PAH may progress silently, even on

the days when you may feel fine1

PAH may progress silently, even on the days when you may feel fine1

Watch the Video
PAH progression doesn’t stop
Why should you?
Sign up to learn more
Your PAH may be progressing silently, even when your symptoms seem stable1
PAH can involve changes in the levels of three substances that occur naturally in your body. Over time, these changes can cause the arteries in your lungs to become thick and stiff. As this happens, the arteries of your lungs may tighten or narrow and scar, making it more difficult for blood to flow.2,3
When blood flow is restricted, your heart must work harder to pump blood through the arteries of your lungs. This can cause the muscles in your heart to thicken, which can make it more difficult for your heart to pump blood. As time goes on, the strain on your heart can progressively worsen.3
Watch this video
to learn more
The Quiz
Question 1
When my symptoms are stable, that means my pulmonary arterial hypertension (PAH) is not getting worse.
True False
THE CORRECT ANSWER IS FALSE
Even when symptoms seem stable, your PAH may be progressing. The narrowing of the arteries in your lungs can make the heart work harder, increasing the strain on your heart.3
Next Question
Question 2
PAH involves changes in the levels of only two naturally occurring substances in the body.
True False
THE CORRECT ANSWER IS FALSE
PAH can be driven by imbalances of three substances that occur naturally in your body. Over time, the changes in these substances can cause the arteries in your lungs to become thick and stiff.2
Next Question
Question 3
There are PAH treatments available that target three different pathways.
True False
THE CORRECT ANSWER IS TRUE
There are medications available that work on each of the three key pathways.2 UPTRAVI® targets one of these pathways. Discussing a comprehensive treatment plan with your doctor that includes UPTRAVI® may help you delay the progression of your PAH.4
Finish Quiz
PAH can progress rapidly in patients with connective tissue disease such as scleroderma5
If you have PAH associated with scleroderma, you may want to learn how it might affect you.
Learn more about scleroderma and PAH
Find out if there is an additional treatment angle you could try to help delay PAH progression3
Learn more
IMPORTANT SAFETY INFORMATION
EXPAND +
+
IMPORTANT SAFETY INFORMATION
+
What is UPTRAVI®?
IMPORTANT SAFETY INFORMATION
References: 1. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143-155. 2. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189-2208. 3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294. 4. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 5. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii25-31.
×